A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jul 1, 2020

Keywords

ClinConnect Summary

This clinical trial is investigating the use of platelet-rich plasma (PRP) treatment to help women with breast cancer who are experiencing hair loss after their cancer therapy. PRP is made from a sample of your own blood, which is processed to concentrate the platelets, and then injected into your scalp. The study will involve participants receiving these injections every four weeks for a total of 12 weeks.

To be eligible for this trial, women must be at least 18 years old and have specific types of hair loss related to cancer treatment, either from hormone therapy or chemotherapy. Participants cannot be pregnant, breastfeeding, or have certain scalp conditions. If you decide to join, you can expect regular visits to receive the treatment and will be asked not to use any hair loss products during the study. This trial aims to see if PRP can help improve hair regrowth in women who have struggled with hair loss after their cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Women ≥ 18 years of age
• * Have a clinical diagnosis of endocrine therapy induced alopecia (EIA) for breast cancer:
• • Selective estrogen receptor modulators (tamoxifen, toremifene)
• • Aromatase inhibitors (anastrozole, letrozole, exemestane)
• • Gonadotropin-releasing hormone agonist (leuprolide)
• • OR
• • Must have a clinical diagnosis of chemotherapy induced (pCIA) alopecia with incomplete or absent regrowth of hair \> 3 months after completion of chemotherapy without use of endocrine cancer-related therapy (ET) within the last 6 months
• • Ludwig stage 1-3 for women
• • If patient has a history of use of topical minoxidil and/or systemic spironolactone for alopecia for at least three consecutive months, then a 3 month washout is required prior to start of treatment
• • Completed informed consent form
• Exclusion Criteria:
• • Patients who are pregnant or breastfeeding
• • History of hair transplantation
• • Use of any cosmetic product aimed at improving or correcting the signs of hair loss within 2weeks prior to screening. Note: patients are not permitted to use any hair loss products during the study.
• • An active scalp dermatologic condition (e.g. alopecia areata, scalp psoriasis), scalp skin cancer (e.g. BCC, SCC), a pre-existing condition with sequelae on the scalp (e.g. scarring alopecia) or acute infection.
• • Hereditary or acquired hematologic/coagulation disorders such as: platelet dysfunction syndrome, critical thrombocytopenia (platelet count \<150,000 platelets/ul),hypofibrinogenemia, impaired coagulation, drepanocytosis (sickle cell anemia).
• • Actively receiving anticoagulant medication
• • Patients taking Aspirin or other NSAIDs such as Nurofen, Voltaren, Diclofenac or Naproxen, or fish-oil supplements because of its anti-platelet activity, can participate, provided medication is interrupted 7 days before beginning of the treatment.
• • Planned or previous radiation therapy to the brain
• • Vulnerable populations e.g. decisionally impaired (cognitive, psychiatric) or patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent
• • Patients taking hair supplements, such as biotin or biosil, can participate, provided hair supplements are washed out 3 months prior to beginning of treatment.